TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10344626

Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone dipropionate 200 microg day(-1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone dipropionate 400 microg day(-1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone dipropionate 800 microg day(-1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CFC-beclomethasone dipropionate 800 microg day(-1)
Number of subjects: 43

Group type: COMPARATOR
Intervention: HFA-placebo
Number of subjects: 43
Study: 7491331

Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no theophylline treatment)
Number of subjects: 18
Study: 1773467

Group type: EXPERIMENTAL
Intervention: Ligustrazine (120‐160mg/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (magnesium sulfate 20‐25g/d)
Number of subjects: 75
Study: 6114776

Group type: EXPERIMENTAL
Intervention: Gradual withdrawal of benzodiazepines (placebo-controlled, double-blind)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Gradual withdrawal of benzodiazepines
Number of subjects: 16
Study: 31978689

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 31791637

Group type: EXPERIMENTAL
Intervention: BMI ≥45 kg/m2
Number of subjects: 150

Group type: COMPARATOR
Intervention: BMI 35.0‐44.9 kg/m2
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 150
Study: 27704544

Group type: EXPERIMENTAL
Intervention: 8-week mindfulness training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 27282690

Group type: EXPERIMENTAL
Intervention: Conservative treatment using a short leg cast or splint (Group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF) (Group B)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Short leg cast only (Group C)
Number of subjects: 29
Study: 25141360

Group type: EXPERIMENTAL
Intervention: Qigong intervention (3 times per week classes and at least 2 times per week at home)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Qigong intervention
Number of subjects: 40
Study: 23373678

Group type: EXPERIMENTAL
Intervention: Fuld Object-Memory Evaluation (FOME) alternate form
Number of subjects: 102
Study: 19910177

Group type: EXPERIMENTAL
Intervention: Temazepam 10mg at bedtime
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18224400

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (2.5 Gy or more)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study: 16818146

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 14624026

Group type: EXPERIMENTAL
Intervention: Daily dosage of vitamin C
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Daily dosage of vitamin E
Number of subjects: 20

Group type: COMPARATOR
Intervention: CSF: plasma ratio of vitamin C
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hippocampal volume in AD patients
Number of subjects: 20
Study: 10900277

Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg orally twice daily) and 0.45 percent saline intravenously
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo and saline
Number of subjects: 83
Study: 8922661

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Continuous combined HRT
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Sequential HRT
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: HRT treatment groups
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 151

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 151
Study: 1447502

Group type: EXPERIMENTAL
Intervention: Standardized meal
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 68
Study: 4064528

Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iopamidol (Niopam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iohexol (Omnipaque)
Number of subjects: 0
Study: 30847930

Group type: EXPERIMENTAL
Intervention: Oestrogen administration (EE)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Endothelin B receptor (ETB R) inhibition (BQ-788)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Lactated Ringer solution alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone
Number of subjects: 27
Study: 30021634

Group type: EXPERIMENTAL
Intervention: Orlistat treatment for 1-3 months before IVF-ET
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment for 1-3 months before IVF-ET
Number of subjects: 0
Study: 26881317

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study: 1582098

Group type: EXPERIMENTAL
Intervention: Oligoantigenic diet
Number of subjects: 21

Group type: COMPARATOR
Intervention: Reintroduction of provoking foods
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo-controlled reintroduction of provoking foods
Number of subjects: 21
Study: 22318199

Group type: EXPERIMENTAL
Intervention: Hydroxyurea/phlebotomy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Transfusions/chelation
Number of subjects: 133
Study: 19793218

Group type: EXPERIMENTAL
Intervention: Hyperoxic aerobic high-intensity interval training (24 sessions, 4x4 min in hyperoxia at 85-95% peak heart rate)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hyperoxic aerobic high-intensity interval training
Number of subjects: 6

Group type: COMPARATOR
Intervention: Acute hyperoxia
Number of subjects: 6
Study: 18775878

Group type: EXPERIMENTAL
Intervention: Active group (discharged 24h after first PM implant or 4-6h after replacement, followed with Home-Monitoring for 4 weeks)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control group (followed for 4 weeks according to usual medical practices)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 379
Study: 16327752

Group type: EXPERIMENTAL
Intervention: Community-based breast cancer screening interventions
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Community-based cervical cancer screening interventions
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combined cervical and breast cancer screening interventions
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Community-based colorectal cancer screening interventions
Number of subjects: 156
Study: 12975409

Group type: EXPERIMENTAL
Intervention: Alpha blocker
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Beta blocker
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Combined alpha and beta blockade
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study: 10656234

Group type: EXPERIMENTAL
Intervention: 600 mg of thioctic acid (TA) t.i.d. for 3 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 9032849

Group type: EXPERIMENTAL
Intervention: Gamma Knife surgery
Number of subjects: 16
Study: 1523284

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (12.5 mg orally)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (25 mg orally)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg orally)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 4043516

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Furosemide-triamterene combination
Number of subjects: 9
Study: 31142081

Group type: EXPERIMENTAL
Intervention: Sublingual 5 mg nifedipine dripping pills
Number of subjects: 482

Group type: COMPARATOR
Intervention: Sublingual 10 mg nifedipine dripping pills
Number of subjects: 482
Study: 29034961

Group type: EXPERIMENTAL
Intervention: Automated intermittent boluses with 16 mg ropivacaine every 2 hours combined with patient-controlled administration
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous infusion of 8 mg/h (4 ml/h) of ropivacaine combined with patient-controlled administration (2 ml, lockout time 30 min)
Number of subjects: 70
Study: 27061887

Group type: COMPARATOR
Intervention: Full dose subcutaneous zoster vaccine
Number of subjects: 224

Group type: COMPARATOR
Intervention: 1/3 dose subcutaneous zoster vaccine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Full dose intradermal zoster vaccine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: 1/3 dose intradermal zoster vaccine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: 1/10 dose intradermal zoster vaccine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: 1/27 dose intradermal zoster vaccine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: All intradermal doses
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Intravenous administration
Number of subjects: 224
Study: 24659236

Group type: EXPERIMENTAL
Intervention: rebamipide (100 mg tid) + LDA (100 mg once-daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo (tid) + LDA
Number of subjects: 32

Group type: COMPARATOR
Intervention: placebo + LDA + clopidogrel (75 mg once-daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: rebamipide + LDA + clopidogrel
Number of subjects: 32
Study: 20435668

Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Number of subjects: 0
Study: 16415603

Group type: EXPERIMENTAL
Intervention: Propranolol 1.0 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Propranolol 0.5 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Saline 1 ml
Number of subjects: 63
Study: 12570169

Group type: EXPERIMENTAL
Intervention: Bromocriptine (7.5 mg continuously) combined with clomiphene citrate (150 mg from day 5 to 9)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo combined with clomiphene citrate (150 mg from day 5 to 9)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bromocriptine and placebo treatment
Number of subjects: 100
Study: 9456562

Group type: EXPERIMENTAL
Intervention: Group I: 38 children (76 eyes) with birth weight from 580 to 1500 g (mean 1158 g)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group II: 52 children (104 eyes) with birth weight from 1501 to 2450 g (mean 2093 g)
Number of subjects: 90
Study: 8147516

Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 100

Group type: COMPARATOR
Intervention: 26-gauge needle
Number of subjects: 100
Study: 2844546

Group type: EXPERIMENTAL
Intervention: RX77368 infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Domperidone during RX77368 infusion
Number of subjects: 6
Study: 11445770

Group type: EXPERIMENTAL
Intervention: Eccentric overload (EO) training, N = 10
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Standard training (ST), N = 10
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (C), N = 10
Number of subjects: 30
Study: 31276454

Group type: EXPERIMENTAL
Intervention: Alcohol dose 1 (0.06%)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alcohol dose 2 (0.08%)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 30127189

Group type: EXPERIMENTAL
Intervention: Video instructions
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Photographic instructions
Number of subjects: 33

Group type: COMPARATOR
Intervention: Visual instructions without video and charts (Group 1)
Number of subjects: 33
Study: 27007062

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200-3000 mg/d)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 24275208

Group type: EXPERIMENTAL
Intervention: Tailored information pack
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (standard information)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study: 22333993

Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin (TC)
Number of subjects: 41
Study: 20598975

Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 266

Group type: COMPARATOR
Intervention: Late invasive strategy
Number of subjects: 266
Study: 17630391

Group type: EXPERIMENTAL
Intervention: AutoCapture-controlled pacing
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional pacing
Number of subjects: 62
Study: 15847313

Group type: EXPERIMENTAL
Intervention: 1% rimexolone
Number of subjects: 78

Group type: COMPARATOR
Intervention: 1% prednisolone acetate
Number of subjects: 78
Study: 11669432

Group type: EXPERIMENTAL
Intervention: Remifentanil anaesthesia (boluses and infusion)
Number of subjects: 20
Study: 9855217

Group type: EXPERIMENTAL
Intervention: Cortical photostimulation with filtered visible light for 12, 14, and 16 minutes for a period of 6 weeks
Number of subjects: 7
Study: 7986390

Group type: COMPARATOR
Intervention: TNF beta * 1 allele in TBII positive atrophic autoimmune thyroiditis patients
Number of subjects: 48

Group type: COMPARATOR
Intervention: HLA-DR8 positive patients with TBII-positive atrophic autoimmune thyroiditis
Number of subjects: 48
Study: 2590268

Group type: EXPERIMENTAL
Intervention: Cefoperazone (n = 5)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Latamoxef (n = 5)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cefotaxime (control, n = 4)
Number of subjects: 14
Study: 4603037

Group type: EXPERIMENTAL
Intervention: Chloroquine-pyrimethamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfalene-pyrimethamine
Number of subjects: 0
Study: 30362981

Group type: EXPERIMENTAL
Intervention: Capacitive and resistive electric transfer (CRET) therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 53
Study: 28249576

Group type: EXPERIMENTAL
Intervention: In-person, group-based intervention (13 sessions; n=215)
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Web-based intervention (13 modules; n=225)
Number of subjects: 651

Group type: COMPARATOR
Intervention: Control group (printed educational materials; n=211)
Number of subjects: 651
Study: 25924668

Group type: EXPERIMENTAL
Intervention: Optimized Option B+ approach (immediate ART initiation upon diagnosis)
Number of subjects: 94000

Group type: COMPARATOR
Intervention: Control group (standard care prior to intervention implementation)
Number of subjects: 94000
Study: 22773282

Group type: EXPERIMENTAL
Intervention: Carotenoid supplementation (0.14 mg lutein + 0.0006 mg zeaxanthin)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo (5% glucose solution)
Number of subjects: 229
Study: 21358498

Group type: EXPERIMENTAL
Intervention: Custom laminated mouthguard with normal palatal surface
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Custom laminated mouthguard with palatal coverage up to the gingival margin
Number of subjects: 27

Group type: COMPARATOR
Intervention: No mouthguard
Number of subjects: 27
Study: 18165564

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (6 microg x kg(‐1) x h(‐1) for 10 min followed by 0.2 microg x kg(‐1) x h(‐1))
Number of subjects: 46

Group type: COMPARATOR
Intervention: Propofol (6 mg x kg(‐1) x h(‐1) for 10 min followed by 2.4 mg x kg(‐1) x h(‐1))
Number of subjects: 46
Study: 17065944

Group type: EXPERIMENTAL
Intervention: Dynamic ankle-foot orthoses (DAFOs)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study: 14872504

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg once daily
Number of subjects: 189

Group type: COMPARATOR
Intervention: Indomethacin 50 mg three times daily
Number of subjects: 189
Study: 10989243

Group type: EXPERIMENTAL
Intervention: FibroPlant‐LNG intrauterine system (IUS) delivering approximately 10 microg per day of LNG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FibroPlant‐LNG intrauterine system (IUS) delivering approximately 14 microg per day of LNG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FibroPlant‐LNG intrauterine system (IUS)
Number of subjects: 30
Study: 9072985

Group type: EXPERIMENTAL
Intervention: Conventional water-based paint
Number of subjects: 17

Group type: COMPARATOR
Intervention: VOC-free paint
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both paints
Number of subjects: 17
Study: 8339215

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, 5-fluorouracil, and prednisone with tamoxifen
Number of subjects: 564

Group type: COMPARATOR
Intervention: Cyclophosphamide, 5-fluorouracil, and prednisone without tamoxifen
Number of subjects: 564
Study: 3537245

Group type: EXPERIMENTAL
Intervention: Furosemide (single dose)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Furosemide (6-10 day course)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Furosemide (long-term therapy)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (7-day control period)
Number of subjects: 16
Study: 29905619

Group type: EXPERIMENTAL
Intervention: MMF capsule
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMF dispersible tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 0
Study: 27637335

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) - 0.092 g EPA+DHA/kg body weight/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard medical care only (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 60
Study: 24378525

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) plus membrane filtration (MF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Immunoadsorption (IA) alone
Number of subjects: 14
Study: 23043944

Group type: EXPERIMENTAL
Intervention: 7-day CIDR protocol
Number of subjects: 543

Group type: COMPARATOR
Intervention: 5-day CIDR protocol
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Sexed semen
Number of subjects: 543
Study: 21079403

Group type: EXPERIMENTAL
Intervention: Jejunal pouch interposition (PO group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Jejunal interposition (IP group)
Number of subjects: 38
Study: 18551124

Group type: EXPERIMENTAL
Intervention: Insulin users (88 participants, 54% of total)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Noninsulin users (75 participants, 46% of total)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Insulin users (after adjustment)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Noninsulin users (after adjustment)
Number of subjects: 163
Study: 15838684

Group type: EXPERIMENTAL
Intervention: Combined use of ultrasonic scaler and Periopolisher diamond‐coated inserts (US‐POL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hand instruments (MANUAL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Perioplaner-Periopolisher system (PPL-POL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Periokit ultrasonic-designed scalers (PERIOKIT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler alone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 40
Study: 12431033

Group type: EXPERIMENTAL
Intervention: Learning and recalling animal tracks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Learning and recalling kitchen implements
Number of subjects: 0
Study: 10353514

Group type: EXPERIMENTAL
Intervention: RRV‐TV vaccine
Number of subjects: 2398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2398
Study: 8626881

Group type: EXPERIMENTAL
Intervention: 80 mg immediate-release (IR) verapamil every 8 hours
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 240 mg controlled-release (CR) formulation once daily
Number of subjects: 11

Group type: COMPARATOR
Intervention: Both formulations (IR and CR)
Number of subjects: 11
Study: 2123907

Group type: EXPERIMENTAL
Intervention: recombinant tissue-type plasminogen activator (rt-PA) (Group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: recombinant tissue-type plasminogen activator (rt-PA) (Group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: conventional therapy (Group C)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Group C (conventional therapy)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group A (rt-PA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group B (rt-PA)
Number of subjects: 34
Study: 6994665

Group type: EXPERIMENTAL
Intervention: Metrifonate at 10 mg/kg body weight for three days
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metrifonate at 10 mg/kg body weight for six days
Number of subjects: 34
Study: 29691983

Group type: EXPERIMENTAL
Intervention: Decoding intervention (15 × 20-min sessions)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Language intervention (control)
Number of subjects: 8
Study: 28948706

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow-derived mononuclear cells (BM-MNCs) 2-8 days after successful reperfusion for AMI added on top of optimal standard of care.
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Optimal standard of care.
Number of subjects: 3000
Study: 26525049

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 23453612

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine pre‐procedure rinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 g amoxicillin antibiotic prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21494037

Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional polypectomy
Number of subjects: 80
Study: 19781270

Group type: EXPERIMENTAL
Intervention: Two-dose steroid combined with two-dose daclizumab and tacrolimus
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional protocol (steroid withdrawn after 3 months)
Number of subjects: 67
Study: 16860496

Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation (3-s stimulus with an artificial larynx)
Number of subjects: 2833

Group type: COMPARATOR
Intervention: Observation time extended for 60 min (Control group B)
Number of subjects: 2833